CLIN1136_1 Vibativ slide deck sect. 6_v4_290514 PROMO

Microbiology!
Telavancin demonstrates a highly potent, broad Gram-positive spectrum1"
MIC, minimum inhibitory concentration; MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus.!
1. Source data: Focus Bio-Inova. Telavancin US and Europe Surveillance 2004−2005.!
Telavancin has a similar MIC range against both MSSA and MRSA1"
MIC, minimum inhibitory concentration; MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus.!
1. Draghi DC, et al. ICAAC 2006. Poster E-0715.!
Telavancin demonstrates superior activity in vitro against MRSA vs other agents1"
MIC, minimum inhibitory concentration.!
1. Source data: Focus Bio-Inova. Telavancin US and Europe Surveillance 2004−2005. 2. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone
diameters. Version 4.0, 2014. http://www.eucast.org!
Telavancin demonstrates potent in vitro activity against S. aureus,
including against multidrug-resistant isolates1 "
MIC, minimum inhibitory concentration; MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; MDR, multidrug-resistant.!
1. Draghi DC, et al. ICAAC 2006. Poster E-0715.!
Telavancin is potent against MRSA with reduced susceptibility to
vancomycin, including VISA and hVISA1 "
MIC, minimum inhibitory concentration.!
1. Kosowska-Shick K et al. Antimicrob Agents Chemother 2009; 53: 4217−24.!
Telavancin demonstrates rapid bactericidal activity in vitro1"
•  Telavancin bactericidal activity at 8 hours takes other agents at least 24 hours to achieve!
MIC, minimum inhibitory concentration"
1. Pace JL et al. Antimicrob Agents Chemother 2003; 47(11): 3602−4.!
Telavancin activity vs vancomycin in biofilm models"
•  The in vitro activity of telavancin against MRSA was compared with vancomycin !
in planktonic culture and biofilms1!
•  Telavancin was more effective than vancomycin against MRSA grown in 3 out of 4
different biofilm systems (and as effective in the 4th)1!
A
Treated with
vancomycin!
Live/Dead staining of 24-h biofilms formed
by one hospital-acquired MRSA isolate !
Green cells = viable!
B
4 x MIC 10 x MIC 100 x MIC Red cells = disrupted membrane integrity!
Treated with
telavancin!
4 x MIC 10 x MIC 100 x MIC •  The MIC range of telavancin was consistently 2- to 16-fold lower than vancomycin for HA
and CA isolates1!
MRSA, methicillin-resistant Staphylococcus aureus; MIC, minimum inhibitory concentration!
1. Smith K et al. Eur J Clin Microbiol Infect Dis 2013; 32:1327-32.!
Telavancin demonstrates a prolonged post-antibiotic effect against
MSSA and MRSA1"
The duration of post antibiotic effect was calculated as the number of hours until return to log-phase growth of treated bacteria minus the time for return of control bacteria (no antibiotic
but treated identically) to log-phase growth.!
MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; GISA, glycopeptide-intermediate S. aureus; ND, not determined. !
1. Pace JL et al. Antimicrob Agents Chemother 2003; 47(11): 3602−4. !
Telavancin demonstrates a low potential for resistance development1"
•  Over 10 days of serial passage, MIC did not change significantly (>1 dilution),
indicating low potential for resistance!
MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; VSSA, vancomycin-susceptible S. aureus; VRSA, vancomycin-resistant S. aureus.!
1. Sahm DF et al. ICAAC 2006. Poster #C1-0681.!
Telavancin microbiology: an overview"
•  First-in-class lipoglycopeptide!
•  Dual mechanism of action1!
•  Inhibition of bacterial cell wall synthesis!
•  Disruption of bacterial cell membrane!
•  Highly potent, broad Gram-positive spectrum2!
•  Rapid bactericidal activity3 !
•  Long post-antibiotic effect3 !
•  Low potential for resistance development4!
1. Leonard SN & Rybak MJ. Pharmacotherapy 2008; 28(4): 458−68. 2. Source data: Focus Bio-Inova. Telavancin US and Europe Surveillance 2004−2005. 3. Pace JL et al. Antimicrob Agents Chemother 2003; 47(11): 3602−4. 4. Sahm DF et al. ICAAC 2006. Poster #C1-0681.!